Original Article
Inhibition of Erythroid Progenitor Cells by Anti-Kell Antibodies in Fetal Alloimmune Anemia
N Engl J Med 1998; 338:798-803March 19, 1998
- Abstract
Background
In alloimmune anemia of the newborn, the level of hemolysis caused by the presence of antibodies to antigens of the Kell blood-group system is less than that caused by antibodies to the D antigen of the Rh blood-group system, and the numbers of reticulocytes and normoblasts in the baby's circulation are inappropriately low for the degree of anemia. These findings suggest that sensitization to Kell antigens results in suppression of fetal erythropoiesis as well as hemolysis.
Methods
We compared the growth in vitro of Kell-positive and Kell-negative hematopoietic progenitor cells from cord blood in the presence of human monoclonal anti-Kell antibodies and anti-D antibodies and serum from women with anti-Kell antibodies.
Results
The growth of Kell-positive erythroid progenitor cells (erythroid burst-forming units and colony-forming units) from cord blood was markedly inhibited by monoclonal IgG and IgM anti-Kell antibodies in a dose-dependent fashion (range of concentrations, 0.2 to 20 percent), but monoclonal anti-D antibodies had no effect. The growth of these types of cells from Kell-negative cord blood was not affected by either type of antibody. Neither monoclonal anti-Kell antibodies nor monoclonal anti-D antibodies inhibited the growth of granulocyte or megakaryocyte progenitor cells from cord blood. Serum from 22 women with anti-Kell antibodies inhibited the growth of Kell-positive erythroid burst-forming units and colony-forming units but not of Kell-negative erythroid burst-forming units and colony-forming units (P<0.001 for the difference between groups). The maternal anti-Kell antibodies had no inhibitory effects on granulocyte–macrophage or megakaryocyte progenitor cells from cord blood.
Conclusions
Anti-Kell antibodies specifically inhibit the growth of Kell-positive erythroid burst-forming units and colony-forming units, a finding that supports the hypothesis that these antibodies cause fetal anemia by suppressing erythropoiesis at the progenitor-cell level.
Media in This Article
Figure 1
Effect of Monoclonal Anti-Kell Antibodies on the Growth of Cord-Blood Erythroid Progenitor Cells.Figure 2
Effect of Maternal Serum Containing Anti-Kell Antibodies on the Growth of Cord-Blood Erythroid Progenitor Cells.Article Activity
- Article
The Kell blood-group system is one of the major antigenic systems in human red cells. It consists of 23 known antigens that reside on one 93-kd transmembrane protein encoded by a single gene on chromosome 7 (7q33).1,2 The Kell antigen is expressed only by erythroid progenitor cells and mature erythroid cells.1,3,4 The Kell blood group is important in clinical medicine because antibodies to the principal antigen, K1, cause both life-threatening transfusion reactions and severe alloimmune anemia in Kell-positive fetuses and newborn infants.5,6 Alloimmunization occurs when Kell-negative women, who do not have the K1 antigen on their red cells, become sensitized by carrying a Kell-positive fetus to produce alloantibodies that may cross the placenta and cause fetal anemia in a Kell-positive, but not a Kell-negative, fetus.
Since the introduction of effective prophylaxis against alloimmunization to the D antigen of the Rh blood-group system, anti-Kell antibodies have accounted for 10 percent of the cases of antibody-mediated severe fetal anemia.7 The mechanism of fetal anemia mediated by anti-Kell antibodies differs in several ways from that of classic hemolytic disease of the newborn associated with anti-D alloantibodies.7-10 Affected Kell-alloimmunized fetuses have lower numbers of circulating reticulocytes and normoblasts than fetuses with hemolytic disease due to anti-D antibodies, and the levels are inappropriately low for the degree of fetal anemia.7,10 In addition, the concentrations of bilirubin in amniotic fluid and in fetal or neonatal serum are lower than those in anti-D alloimmunized fetuses.7,9,11 Also, the titer of anti-Kell antibodies in maternal serum correlates very poorly with the degree of fetal anemia.12 These observations suggest that in Kell alloimmunization fetal anemia is caused by the suppression of erythropoiesis in addition to hemolysis.
This study was undertaken to test the hypothesis that anti-Kell antibodies cause fetal anemia in part by inhibiting the growth of erythroid progenitor cells. We therefore compared the growth of Kell-positive and Kell-negative hematopoietic progenitor cells from cord blood in the presence of human monoclonal anti-Kell antibodies, anti-D antibodies, and serum from Kell-alloimmunized women.
Methods
The study was approved by the institutional review committee of Hammersmith and Queen Charlotte's hospitals, and all samples were collected with informed parental consent.
Cord-Blood Samples
Cells obtained from umbilical-cord blood from uncomplicated deliveries of normal infants at term were used for progenitor-cell assays. The cells were typed as Kell-positive or Kell-negative with monoclonal IgM anti-Kell antibodies (Biotec), and the Rh genotype was determined with antibodies against D, C, c, E, and e (Biotest). Mononuclear cells were isolated from cord blood by density centrifugation, depleted of adherent cells by allowing such cells to adhere to plastic tissue-culture dishes, and cultured in the presence and the absence of monoclonal anti-Kell antibodies, monoclonal anti-D antibodies, serum samples containing anti-Kell antibodies, and control serum samples from pregnant women who had no red-cell alloantibodies.
Assays of Hematopoietic Progenitor Cells
Erythroid Progenitor Cells
Cord-blood mononuclear cells were plated at a density of 200,000 per milliliter (20,000 per well) in microtiter plates containing 1.2 percent methylcellulose supplemented with 20 percent fetal-calf serum, 2 U of erythropoietin per milliliter (Terry Fox Laboratories), 1 percent bovine serum albumin (Sigma), 2-mercaptoethanol, 5 percent 5637 conditioned medium,10 penicillin–streptomycin, and glutamine. The cultures were established in the absence or the presence of serum containing anti-Kell antibodies (20 percent), control serum (20 percent), or serial dilutions of monoclonal anti-Kell or anti-D antibodies (20, 2, 0.2, 0.02, and 0.002 percent). The monoclonal IgM anti-Kell antibodies and anti-D antibodies (both from Biotest) contained azide and were therefore dialyzed to prevent nonspecific inhibition of progenitor-cell growth; the IgG anti-Kell antibodies (Biotec) did not contain azide and therefore were not dialyzed. The IgG monoclonal anti-Kell antibodies and anti-D antibodies were both IgG1. The cultures were incubated in 5 percent carbon dioxide at 37°C, and the number of erythroid colony-forming units was counted after 7 days and the number of erythroid burst-forming units after 14 days. Six wells were plated for each experiment, and the result was calculated as the mean number of colonies per well and expressed as the number of colonies per milliliter of cord blood.
Granulocyte–Macrophage Progenitor Cells
Cord-blood mononuclear cells were plated at a density of 100,000 per milliliter (10,000 per well) in microtiter plates in 0.9 percent methylcellulose supplemented with 10 percent fetal-calf serum, 10 percent 5637 conditioned medium, penicillin–streptomycin, and glutamine in the presence or the absence of serum containing anti-Kell antibodies (20 percent), control serum (20 percent), or serial dilutions of monoclonal anti-Kell or anti-D antibodies (20, 2, and 0.2 percent). The number of granulocyte–macrophage colony-forming units was counted after 14 days of incubation in 5 percent carbon dioxide at 37°C. The result was calculated as the mean number of colonies per well (six wells per experiment) and expressed as the number per milliliter of cord blood.
Megakaryocyte Progenitor Cells
Cord-blood mononuclear cells were cultured at a density of 200,000 per milliliter (20,000 per well) in agar in microtiter plates as previously described13 in the presence or the absence of serum containing anti-Kell antibodies (20 percent), control serum (20 percent), or serial dilutions of monoclonal anti-Kell or anti-D antibodies (20, 2, and 0.2 percent). The number of megakaryocyte burst-forming units and colony-forming units was counted after 21 days, and the megakaryocytic lineage of the cells was confirmed by staining with monoclonal antibodies against platelet glycoprotein IIb/IIIa (CD61, Becton Dickinson) with the alkaline phosphatase–anti-alkaline phosphatase technique. Six wells were plated for each experiment, and the result was calculated as the mean number of colonies per well and expressed as the number per milliliter of cord blood.
Test and Control Serum Samples
Serum samples from 22 pregnant women found to have anti-Kell antibodies on routine screening during early pregnancy were collected at a median duration of gestation of 28 weeks (range, 23 to 30). These women represented the entire cohort of Kell-immunized pregnant women who were seen at Queen Charlotte's Hospital during the study period (1992 to 1996). Twelve of their fetuses were Kell-positive, with severe anemia detected by fetal-blood sampling, and required serial intrauterine transfusions. The remaining 10 fetuses underwent fetal-blood sampling for Kell grouping. Of these, three fetuses were Kell-positive and had mild anemia, neonatal phototherapy being the sole treatment required. The remaining seven women had a Kell-negative fetus and had not required intrauterine therapy in any previous Kell-positive pregnancies. Serum samples were collected serially during pregnancy from eight of the women whose fetuses had severe anemia. In all cases, clotted blood was separated within four hours after collection and the serum was stored at -20°C until tested. Anti-Kell antibodies were identified and measured with standard serologic methods.14 Five of the women had other red-cell alloantibodies: two had anti-c antibodies and one each had anti-C, anti-D, and anti-Jka antibodies (Kidd blood group). For these five women all assays used cord-blood progenitor cells that did not contain the antigen to which they had alloantibodies. As additional controls, 11 maternal serum samples containing no red-cell alloantibodies were tested for their effects on erythroid burst-forming units and colony-forming units, granulocyte–macrophage colony-forming units, and megakaryocyte burst-forming units and colony-forming units.
Statistical Analysis
Data were analyzed by parametric or nonparametric methods as appropriate. Paired and unpaired comparisons were carried out with the two-sided Student's t-test or Wilcoxon test and the Mann–Whitney U test, respectively. Pearson's correlation coefficient was only used when the least-squares method supported a linear relation. For linear regression analysis of two separate groups, the slopes were compared with use of the test for the equality of regression coefficients and the positions by analysis of covariance.
Results
Effect of Monoclonal Anti-Kell Antibodies on Cord-Blood Hematopoietic Progenitor Cells
Erythroid Burst-Forming Units and Colony-Forming Units
The monoclonal IgG anti-Kell antibodies caused dose-dependent inhibition of the growth of cord-blood erythroid progenitor cells from Kell-positive but not Kell-negative infants (Figure 1AFigure 1
Effect of Monoclonal Anti-Kell Antibodies on the Growth of Cord-Blood Erythroid Progenitor Cells. and Figure 1B). The growth of Kell-positive cells was inhibited at all but the lowest concentrations of IgG monoclonal anti-Kell antibodies. The monoclonal IgM anti-Kell antibodies also caused similar dose-dependent inhibition of the growth of Kell-positive cells and no inhibition of Kell-negative cells, even at the highest concentration of antibody (20 percent). The growth of the more immature erythroid progenitor cells, erythroid burst-forming units, was inhibited more than that of the mature erythroid progenitor cells, erythroid colony-forming units, for any given concentration of monoclonal IgG or monoclonal IgM anti-Kell antibodies (P = 0.01). Monoclonal anti-D antibodies caused no inhibition of cord-blood erythroid burst-forming units or colony-forming units from five Kell-positive, D-positive infants (data not shown). Because the monoclonal anti-Kell antibodies and the monoclonal anti-D antibodies used in these experiments were both of the IgG1 subclass, the inhibitory effect on Kell-positive erythroid progenitor cells was specific for anti-Kell antibodies rather than representative of nonspecific inhibition by IgG1 antibodies.Granulocyte–Macrophage Progenitor Cells
The monoclonal IgG anti-Kell antibodies did not inhibit the growth of Kell-positive or Kell-negative granulocyte–macrophage progenitor cells from cord blood (Table 1Table 1
Effect of Monoclonal IgG Anti-Kell Antibodies on the Growth of Kell-Positive and Kell-Negative Granulocyte–Macrophage Progenitor Cells and Megakaryocyte Progenitor Cells from Cord Blood.). Similarly, monoclonal IgG anti-D antibodies did not inhibit the growth of granulocyte–macrophage progenitor cells from cord blood from Kell-positive, D-positive infants.Megakaryocyte Progenitor Cells
The monoclonal anti-Kell antibodies also did not inhibit the growth of Kell-positive or Kell-negative megakaryocyte progenitor cells from cord blood. The results of the studies with monoclonal IgG antibodies are shown in Table 1. Similarly, there was no significant difference between groups in the number of megakaryocyte burst-forming units and colony-forming units grown in the presence of monoclonal IgM anti-Kell antibodies. The monoclonal IgG anti-D antibodies did not inhibit the formation of megakaryocyte burst-forming units and colony-forming units in cord blood from Kell-positive, D-positive donors.
Effect of Maternal Serum Containing Anti-Kell Antibodies on Cord-Blood Hematopoietic Progenitor Cells
Serum samples from 22 women with anti-Kell antibodies were tested for their ability to inhibit the growth of Kell-positive and Kell-negative erythroid burst-forming units or colony-forming units in cord blood. All 22 samples significantly inhibited the growth of erythroid burst-forming units from Kell-positive samples (median degree of inhibition, 59 percent; range, 16 to 85; P<0.001) but not Kell-negative samples (median degree of inhibition, 4 percent; range, 0 to 30) (Figure 2AFigure 2
Effect of Maternal Serum Containing Anti-Kell Antibodies on the Growth of Cord-Blood Erythroid Progenitor Cells.). Maternal serum also inhibited the growth of erythroid colony-forming units from Kell-positive samples of cord blood (median degree of inhibition, 26 percent; range, 7 to 78; P<0.001) but not from Kell-negative samples (median degree of inhibition, 4 percent; range, 0 to 28) (Figure 2B). The degree of inhibition was more variable than with the monoclonal anti-Kell antibodies. There was significantly greater inhibition of the more immature progenitor cells, erythroid burst-forming units, than of erythroid colony-forming units (P<0.001). The serum samples containing anti-Kell antibodies caused no significant inhibition of Kell-positive or Kell-negative granulocyte–macrophage colony-forming units, megakaryocyte burst-forming units, or megakaryocyte colony-forming units (Table 2Table 2
Effect of Maternal Serum Containing Anti-Kell Antibodies or No Red-Cell Alloantibodies on Granulocyte–Macrophage and Megakaryocyte Progenitor Cells.). For the eight women for whom serial samples were analyzed, there was no effect of duration of gestation on the degree of inhibition of erythroid burst-forming units or colony-forming units (data not shown). Maternal serum samples without red-cell alloantibodies had no effect on Kell-positive or Kell-negative erythroid burst-forming units or colony-forming units (Table 3Table 3
Effect of Maternal Serum Containing Anti-Kell Antibodies or No Red-Cell Alloantibodies on Erythroid Progenitor Cells from Cord Blood.).Effect of Severity of Disease
Maternal serum samples containing anti-Kell antibodies from the fetuses with severe anemia inhibited Kell-positive erythroid burst-forming units to a greater extent than serum samples from women whose fetuses had mild anemia (Table 4Table 4
Relation between the Severity of Fetal Anemia and Maternal Anti-Kell Antibody Titers and the Degree of Inhibition of Erythroid Burst-Forming Units and Colony-Forming Units in Cord Blood.). There was no difference between groups in the degree of inhibition of erythroid colony-forming units, and there was no correlation between the anti-Kell antibody titer and the degree of inhibition of either erythroid burst-forming units or colony-forming units. The median anti-Kell antibody titer was significantly higher in the women whose fetuses had severe anemia than in the women whose fetuses had mild anemia.Discussion
Kell-alloimmunized fetuses have fewer circulating reticulocytes and normoblasts than fetuses affected by anti-D antibodies, suggesting that erythroid suppression is the mechanism responsible for this type of anemia.7,10 Our data confirm this hypothesis by demonstrating that both human monoclonal anti-Kell antibodies and serum samples from women with anti-Kell antibodies specifically inhibit erythroid progenitor cells from Kell-positive but not Kell-negative cord blood and that the inhibition is dose dependent, specific for cells of the erythroid lineage, and specific for anti-Kell antibodies.
The greater inhibitory effect of both monoclonal anti-Kell antibodies and maternal serum on the more immature erythroid cells (erythroid burst-forming units) was also reflected in the clinical severity of the fetal anemia and may indicate the importance of the Kell antigen at a specific stage in erythroid differentiation. Alternatively, the apparently greater inhibition of erythroid burst-forming units by maternal serum may represent the wide variation in inhibition of erythroid progenitors by human serum, which contains many stimulatory and inhibitory cytokines.15 In addition, we did not concentrate or purify the serum samples, which may have reduced the variability and increased the correlation between the inhibition of erythroid burst-forming units and colony-forming units, the maternal anti-Kell antibody titer, and the severity of disease.
The Kell antigen is known to be expressed early in fetal life16 and on immature erythroid cells. It is therefore not surprising that erythroid burst-forming units and colony-forming units were inhibited by anti-Kell antibodies. That granulocyte–macrophage and megakaryocyte progenitors from the same Kell-positive fetuses were not inhibited by anti-Kell antibodies is consistent with previous findings of the restriction of Kell messenger RNA and protein to cells of erythroid lineage.3,4
Little is known about the function of the Kell protein. It is a transmembrane protein with sequence and structural similarities to endopeptidases that process peptide hormones and may be expressed on early hematopoietic cells.17-21 The putative endopeptidase region of the Kell gene has 59 percent homology with the common acute lymphoblastic leukemia antigen,21,22 which is a functional endopeptidase. Therefore, the common acute lymphoblastic leukemia antigen and Kell may have a role in regulating the growth and differentiation of the cells on which they are expressed, perhaps by modulating peptide growth factors on the cell surface.23
Our data have implications for the care of pregnancies in which Kell alloimmunization is identified either by the detection of anti-Kell antibodies at routine pregnancy screening or on the basis of a history of a previous fetus with anemia. Detecting hemolysis indirectly by measuring the concentration of bilirubin in amniotic fluid is unlikely to be helpful, since bilirubin concentrations in Kell-alloimmunized fetuses do not reflect the severity of fetal anemia.7,10 Management of pregnancies involving Kell alloimmunization should focus on Kell genotyping of fetal DNA24 when the father is heterozygous for K1 and monitoring the Kell-positive fetus for the development of anemia by cordocentesis and serial ultrasonography.
In conclusion, both monoclonal and naturally occurring anti-Kell antibodies inhibit the growth of Kell-positive erythroid progenitor cells. These findings suggest that suppression of erythropoiesis at the progenitor-cell level is an important mechanism of fetal anemia due to anti-Kell antibodies.
Supported by funds from the special trustees of the Hammersmith and Queen Charlotte's Special Health Authority.
We are indebted to Ms. Caroline Sweet and Mrs. Helen Karim, research midwives at Queen Charlotte's Hospital, London, who collected all the cord-blood samples.
Source Information
From the Departments of Obstetrics and Haematology, Institute of Obstetrics and Gynaecology, Queen Charlotte's Hospital (J.I.V., R.M.W., E.A.L.), and the Department of Haematology, Imperial College School of Medicine at the Royal Postgraduate Medical School (M.M., N.A.M., I.A.G.R.) — both in London.
Address reprint requests to Dr. Roberts at the Department of Haematology, Imperial College School of Medicine at the Royal Postgraduate Medical School, Du Cane Rd., London W12 0NN, United Kingdom.
- References
References
1
Lee S ,Zambas ED ,Marsh WL ,Redman CM . The human Kell blood group gene maps to chromosome 7q33 and its expression is restricted to erythroid cells. Blood 1993;81:2804-2809
Web of Science | Medline2
Redman CM, Lee S. Kell blood group system and the McLeod syndrome. In: Cartron J-P, Rouger P, eds. Blood cell biochemistry. Vol. 6. Molecular basis of human blood group antigens. New York: Plenum Press, 1995:227-42.
3
McGinniss MH ,Dean A . Expression of red cell antigens by K562 human leukemia cells before and after induction of hemoglobin synthesis by hemin. Transfusion 1985;25:105-109
CrossRef | Web of Science | Medline4
Jaber A ,Loirat MJ ,Willem C ,Bloy C ,Cartron JP ,Blanchard D . Characterization of murine monoclonal antibodies directed against the Kell blood group glycoprotein. Br J Haematol 1991;79:311-315
CrossRef | Web of Science | Medline5
Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 9th ed. Oxford, England: Blackwell Scientific, 1993:581-2.
6
Vaughan JI ,Warwick R ,Welch CR ,Letsky EA . Anti-Kell in pregnancy. Br J Obstet Gynaecol 1991;98:944-945
Medline7
Vaughan JI ,Warwick R ,Letsky E ,Nicolini U ,Rodeck CH ,Fisk NM . Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994;171:247-252
Web of Science | Medline8
Farr V ,Gray E . Pregnancy outcome in mothers who develop Kell antibodies. Scott Med J 1988;33:300-303
Web of Science | Medline9
Leggat HM ,Gibson JM ,Barron SL ,Reid MM . Anti-Kell in pregnancy. Br J Obstet Gynaecol 1991;98:162-165
CrossRef | Medline10
Weiner CP ,Widness JA . Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol 1996;174:547-551
CrossRef | Web of Science | Medline11
Nicolaides KH ,Rodeck CH ,Mibashan RS ,Kemp JR . Have Liley charts outlived their usefulness? Am J Obstet Gynecol 1986;155:90-94
Web of Science | Medline12
Bowman JM ,Pollock JM ,Manning FA ,Harman CR ,Menticoglou S . Maternal Kell blood group alloimmunization. Obstet Gynecol 1992;79:239-244
Web of Science | Medline13
Murray NA ,Roberts IAG . Circulating megakaryocytes and their progenitors (BFU-MK and CFU-MK) in term and pre-term neonates. Br J Haematol 1995;89:41-46
Web of Science | Medline14
Contreras M, Knight RC. General approach to blood transfusion and immunohaematology. In: Chanarin I, ed. Laboratory haematology: an account of laboratory techniques. Edinburgh, Scotland: Churchill Livingstone, 1987:403-4.
15
Greer IA ,Lyall F ,Perera T ,Boswell F ,Macara LM . Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction. Obstet Gynecol 1994;84:937-940
Web of Science | Medline16
Marsh WL ,Redman CM . The Kell blood group system: a review. Transfusion 1990;30:158-167
CrossRef | Web of Science | Medline17
Lee S ,Zambas ED ,Green ED ,Redman C . Organization of the gene encoding the human Kell blood group protein. Blood 1995;85:1364-1370
Web of Science | Medline18
Lee S ,Zambas ED ,Marsh WL ,Redman CM . Molecular cloning and primary structure of Kell blood group protein. Proc Natl Acad Sci U S A 1991;88:6353-6357
CrossRef | Web of Science | Medline19
Jongeneel CV ,Bouvier J ,Bairoch A . A unique signature identifies a family of zinc-dependent metallopeptidases. FEBS Lett 1989;242:211-214
CrossRef | Web of Science | Medline20
Shipp MA ,Vijayaraghavan J ,Schmidt EV , et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (“enkephalinase“): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A 1989;86:297-301
CrossRef | Web of Science | Medline21
Wu Q ,Lahti JM ,Air GM ,Burrows PD ,Cooper MD . Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-dependent metallopeptidase family. Proc Natl Acad Sci U S A 1990;87:993-997
CrossRef | Web of Science | Medline22
Lee S ,Wu X ,Reid M ,Zelinski T ,Redman C . Molecular basis of the Kell (K1) phenotype. Blood 1995;85:912-916
Web of Science | Medline23
Kenny AJ ,O'Hare MJ ,Gusterson BA . Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989;2:785-787
CrossRef | Web of Science | Medline24
Avent ND ,Martin PG . Kell typing by allele-specific PCR (ASP). Br J Haematol 1996;93:728-730
CrossRef | Web of Science | Medline
- Citing Articles (63)
Citing Articles
1
Naoko Sasamoto, Takuji Tomimatsu, Keisuke Nagamine, Machiko Oshida, Hirokazu Kashiwagi, Shinsuke Koyama, Takeshi Kanagawa, Hitomi Arahori, Yoshiaki Tomiyama, Tadashi Kimura. (2011) Fetal and neonatal anemia associated with anti-Jra: A case report showing a poorly hemolytic mechanism. Journal of Obstetrics and Gynaecology Research 37:8, 1132-1136
CrossRef2
Sharon Markham Geaghan. (2011) Diagnostic Laboratory Technologies for the Fetus and Neonate with Isoimmunization. Seminars in Perinatology 35:3, 148-154
CrossRef3
M. E. A. Rath, V. E. H. J. Smits-Wintjens, I. T. M. Lindenburg, A. Brand, I. L. van Kamp, D. Oepkes, F. J. Walther, E. Lopriore. (2011) Exchange transfusions and top-up transfusions in neonates with Kell haemolytic disease compared to Rh D haemolytic disease. Vox Sanguinis 100:3, 312-316
CrossRef4
Mauro H. Schenone, Giancarlo Mari. (2011) The MCA Doppler and its Role in the Evaluation of Fetal Anemia and Fetal Growth Restriction. Clinics in Perinatology 38:1, 83-102
CrossRef5
G Daniels. 2011. Blood groups on red cells, platelets and neutrophils. , 599-617.
CrossRef6
Deepak Louis, Sapna Oberoi, Venkataseshan Sundaram, Amita Trehan. (2010) Isolated Early Onset Anemia After Rh Isoimmunization: A Unique Presentation in 3 Neonates. Journal of Pediatric Hematology/Oncology 32:6, e230-e232
CrossRef7
E. S. Wester, R. Steffensen, P. C. Ligthart, J. Vad, M. De Haas, J. R. Storry, M. L. Olsson. (2010) KEL*02 alleles with alterations in and around exon 8 in individuals with apparent KEL:1,−2 phenotypes. Vox Sanguinis 99:2, 150-157
CrossRef8
Kenneth J. Moise. 2010. Rh and Other Blood Group Alloimmunizations. , 432-441.
CrossRef9
Isabel Dorn, Peter Schlenke, Christoph Härtel. (2010) Prolonged anemia in an intrauterine-transfused neonate with Rh-hemolytic disease: no evidence for anti-D-related suppression of erythropoiesis in vitro. Transfusion 50:5, 1064-1070
CrossRef10
D. J. Anstee. (2009) Red cell genotyping and the future of pretransfusion testing. Blood 114:2, 248-256
CrossRef11
Sophie Waldvogel, Julia Natterer, Giorgia Canellini, Anita Truttmann, Jean-Daniel Tissot. (2009) Severe neonatal hyporegenerative anemia due to anti-Vw (anti-MNS9) alloantibody. Journal of Perinatal Medicine 37:4, 422-424
CrossRef12
Denise K. Holmes, Ilaria Bellantuono, Steve A. Walkinshaw, Zarko Alfirevic, Tracey A. Johnston, Nimish V. Subhedar, Rachel Chittick, Richard Swindell, Robert F. Wynn. (2009) Telomere length dynamics differ in foetal and early post-natal human leukocytes in a longitudinal study. Biogerontology 10:3, 279-284
CrossRef13
Günther F. Körmöczi, Erwin A. Scharberg, Christoph Gassner. (2009) A novel KEL * 1,3 allele with weak Kell antigen expression confirming the cis-modifier effect of KEL3. Transfusion 49:4, 733-739
CrossRef14
Ketan Gajjar, Chris Spencer. (2009) Diagnosis and management of non-anti-D red cell antibodies in pregnancy. The Obstetrician & Gynaecologist 11:2, 89-95
CrossRef15
L. Vandy Black, Akhil Maheshwari. (2009) Disorders of the Fetomaternal Unit: Hematologic Manifestations in the Fetus and Neonate. Seminars in Perinatology 33:1, 12-19
CrossRef16
Marija Tasic, Jelena Milosevic, Milan Stefanovic, Dragana Radovic-Janosevic, Miljan Krstic, Vladimir Antic. (2009) Kell immunization: A case report. Medicinski pregled 62:7-8, 369-372
CrossRef17
Thierry Peyrard, Bach-Nga Pham, Lionel Arnaud, Sophie Fleutiaux, Yves Brossard, Bénédicte Guerin, Isabelle Desmoulins, Philippe Rouger, Pierre-Yves Le Pennec. (2008) Fatal hemolytic disease of the fetus and newborn associated with anti-Jr a. Transfusion 48:9, 1906-1911
CrossRef18
Kenneth J. Moise. (2008) Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Seminars in Fetal and Neonatal Medicine 13:4, 207-214
CrossRef19
Irene A.G. Roberts. (2008) The changing face of haemolytic disease of the newborn. Early Human Development 84:8, 515-523
CrossRef20
V.E.H.J. Smits-Wintjens, F.J. Walther, E. Lopriore. (2008) Rhesus haemolytic disease of the newborn: Postnatal management, associated morbidity and long-term outcome. Seminars in Fetal and Neonatal Medicine 13:4, 265-271
CrossRef21
E. S. A. van den Akker, F. J. C. M. Klumper, A. Brand, H. H. H. Kanhai, D. Oepkes. (2008) Kell alloimmunization in pregnancy: associated with fetal thrombocytopenia?. Vox Sanguinis 95:1, 66-69
CrossRef22
Juan C. Santiago, Domingo Ramos-Corpas, Salvador Oyonarte, Francisco Montoya. (2008) Current clinical management of anti-Kell alloimmunization in pregnancy. European Journal of Obstetrics & Gynecology and Reproductive Biology 136:2, 151-154
CrossRef23
Janet Brennand, Alan Cameron. (2008) Fetal anaemia: diagnosis and management. Best Practice & Research Clinical Obstetrics & Gynaecology 22:1, 15-29
CrossRef24
Kenneth J. Moise. (2008) The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. American Journal of Obstetrics and Gynecology 198:2, 161.e1-161.e4
CrossRef25
Michael F. Murphy, Lorna M. Williamson. (2008) Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the uk national screening committee. British Journal of Haematology 111:3, 726
CrossRef26
K. Ridgwell, J. Dixey, M. L. Scott. (2007) Production of soluble recombinant proteins with Kell, Duffy and Lutheran blood group antigen activity, and their use in screening human sera for Kell, Duffy and Lutheran antibodies. Transfusion Medicine 17:5, 384-394
CrossRef27
, A. Gooch, J. Parker, J. Wray, H. Qureshi. (2007) Guideline for blood grouping and antibody testing in pregnancy. Transfusion Medicine 17:4, 252-262
CrossRef28
YanYun Wu, Gary Stack. (2007) Blood Product Replacement in the Perinatal Period. Seminars in Perinatology 31:4, 262-271
CrossRef29
Soohee Lee. (2007) The value of DNA analysis for antigens of the Kell and Kx blood group systems. Transfusion 47:s1, 32S-39S
CrossRef30
Agneta Wikman, Ann Edner, Gunilla Gryfelt, Baldvin Jonsson, Jan-Inge Henter. (2007) Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion 47:5, 911-917
CrossRef31
E. Rimon, R. Peltz, R. Gamzu, S. Yagel, B. Feldman, B. Chayen, R. Achiron, S. Lipitz. (2006) Management of Kell isoimmunization — evaluation of a Doppler-guided approach. Ultrasound in Obstetrics and Gynecology 28:6, 814-820
CrossRef32
Gregory A. Denomme, Ali Shahcheraghi, Douglas P. Blackall, Krishna K. Oza, George Garratty. (2006) Inhibition of erythroid progenitor cell growth by anti-Ge3. British Journal of Haematology 133:4, 443-444
CrossRef33
Kenneth J. Moise. (2005) Red Blood Cell Alloimmunization in Pregnancy. Seminars in Hematology 42:3, 169-178
CrossRef34
Jeffrey J. Pu, Colvin M. Redman, Jan W.M. Visser, Soohee Lee. (2005) Onset of expression of the components of the Kell blood group complex. Transfusion 45:6, 969-974
CrossRef35
P. A. Arndt, G. Garratty, G. Daniels, C. A. Green, A. M. Wilkes, P. Hunt, J. Do, S. Glenn, D. Peterson. (2005) Late onset neonatal anaemia due to maternal anti-Ge: possible association with destruction of eythroid progenitors. Transfusion Medicine 15:2, 125-132
CrossRef36
Elisabet S. Wester, Jill R. Storry, Karin Schneider, Birgitta Nilsson Sojka, Joyce Poole, Martin L. Olsson. (2005) Genetic basis of the K 0 phenotype in the Swedish population. Transfusion 45:4, 545-549
CrossRef37
N. Win, P. Amess, M. Needs, P. E. Hewitt. (2005) Use of red cells preserved in extended storage media for exchange transfusion in anti-k haemolytic disease of the newborn. Transfusion Medicine 15:2, 157-160
CrossRef38
H. van Dongen, F. J. C. M. Klumper, E. Sikkel, F. P. H. A. Vandenbussche, D. Oepkes. (2005) Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. Ultrasound in Obstetrics and Gynecology 25:4, 341-345
CrossRef39
Jose L. Bartha, Gayle Harrison, Phillipa M. Kyle, Peter W. Soothill. (2003) Fetal serum alpha-fetoprotein in alloimmunised pregnancies. Prenatal Diagnosis 23:11, 917-920
CrossRef40
Geoff Daniels, Andrew Hadley, Carole A. Green. (2003) Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 43:1, 115-116
CrossRef41
M.F. Murphy, L.M. Williamson, S.J. Urbaniak. (2002) Antenatal Screening for Fetomaternal Alloimmune Thrombocytopenia: Should we be doing it?. Vox Sanguinis 83, 409-416
CrossRef42
Kevin Harrington, Abdalla Fayyad. (2002) Prediction of fetal anaemia. Current Opinion in Obstetrics and Gynecology 14:2, 177-185
CrossRef43
T. Wagner, G. Lanzer, K. Geissler. (2002) Kell Expression on Myeloid Progenitor Cells. Leukemia & Lymphoma 43:3, 479-485
CrossRef44
W. John Judd, . (2001) Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion 41:11, 1445-1452
CrossRef45
S. Stanworth, P. Fleetwood, M. de Silva. (2001) Severe haemolytic disease of the newborn due to anti-Jsb. Vox Sanguinis 81:2, 134-135
CrossRef46
Margriet Huisman, Johannes Egberts, Jenny van Loon. (2001) Derivated fetal haemoglobin as a marker for red cell age in the human fetus reflecting stimulated or impaired red blood cell production. Prenatal Diagnosis 21:7, 523-528
CrossRef47
M. C. Fernández-Jiménez, M. T. Jiménez-Marco, D. Hernández, A. González, F. Omeñaca, C. de la Cámara. (2001) Treatment with plasmapheresis and intravenous immunoglobulin in pregnancies complicated with anti-PP 1 P k or anti-K immunization: a report of two patients. Vox Sanguinis 80:2, 117-120
CrossRef48
Kavita M. Dhodapkar, Francine Blei. (2001) Treatment of Hemolytic Disease of the Newborn Caused by Anti-Kell Antibody With Recombinant Erythropoietin. Journal of Pediatric Hematology/Oncology 23:1, 69-70
CrossRef49
Michael F. Murphy, Lorna M. Williamson. (2000) Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the uk national screening committee. British Journal of Haematology 111:3, 726-732
CrossRef50
Abdellah Ahaded, Yves Brossard, Martine Debbia, Patrick Lambin. (2000) Quantitative determination of anti-K (KEL1) IgG and IgG subclasses in the serum of severely alloimmunized pregnant women by ELISA. Transfusion 40:10, 1239-1245
CrossRef51
K Moise. (2000) Non-anti-D antibodies in red-cell alloimmunization. European Journal of Obstetrics & Gynecology and Reproductive Biology 92:1, 75-81
CrossRef52
T. Wagner, A. Berer, G. Lanzer, K. Geissler. (2000) Kell is not restricted to the erythropoietic lineage but is also expressed on myeloid progenitor cells. British Journal of Haematology 110:2, 409-411
CrossRef53
Wagner, Thomas, , Bernaschek, Gerhard, Geissler, Klaus, . (2000) Inhibition of Megakaryopoiesis by Kell-Related Antibodies. New England Journal of Medicine 343:1, 72-72
Full Text54
Soohee Lee, David Russo, Colvin Redman. (2000) Functional and structural aspects of the kell blood group system. Transfusion Medicine Reviews 14:2, 93-103
CrossRef55
Soohee Lee, David Russo, Colvin M Redman. (2000) The Kell blood group system: Kell and XK membrane proteins. Seminars in Hematology 37:2, 113-121
CrossRef56
S. R. Grant, M. D. Kilby, L. Meer, J. B. Weaver, G. S. Gabra, M. J. Whittle. (2000) The outcome of pregnancy in Kell alloimmunisation. BJOG: An International Journal of Obstetrics and Gynaecology 107:4, 481-485
CrossRef57
Marion E Reid, Maria Rios, Karina Yazdanbakhsh. (2000) Applications of molecular biology techniques to transfusion medicine. Seminars in Hematology 37:2, 166-176
CrossRef58
A. Zeidman, Z. Fradin, Y. Barac, D. Bendayan, M. Mittelman, J. Orlin. (2000) Splenic Lymphoma Presenting as Warm Autoimmune Hemolytic Anemia Associated with Pure Red Cell Aplasia. Vox Sanguinis 78:2, 126-129
CrossRef59
Colvin M Redman, David Russo, Soohee Lee. (1999) Kell, Kx and the McLeod syndrome. Best Practice & Research Clinical Haematology 12:4, 621-635
CrossRef60
Viviane Bony, Pierre Gane, Pascal Bailly, Jean-Pierre Cartron. (1999) Time-course expression of polypeptides carrying blood group antigens during human erythroid differentiation. British Journal of Haematology 107:2, 263-274
CrossRef61
G. Daniels. (1999) Functional aspects of red cell antigens. Blood Reviews 13:1, 14-35
CrossRef62
J.P. Cartron, P. Bailly, C. Le Kim, B. Cherif-Zahar, G. Matassi, O. Bertrand, Y. Colin. (1998) Insights into the Structure and Function of Membrane Polypeptides Carrying Blood Group Antigens. Vox Sanguinis 74:S2, 29-64
CrossRef63
Luban, Naomi L.C., . (1998) Hemolytic Disease of the Newborn: Progenitor Cells and Late Effects. New England Journal of Medicine 338:12, 830-831
Full Text
